32.05
Surmodics Inc stock is traded at $32.05, with a volume of 101.42K.
It is down -1.20% in the last 24 hours and up +10.48% over the past month.
Surmodics Inc is a provider of performance coating technologies for intravascular medical devices and chemical and biological components for in vitro diagnostic (IVD) immunoassay tests and microarrays. The company's reportable segments are; Medical Device and In Vitro Diagnostics. Maximum revenue for the company is derived from its Medical Device segment which is involved in the manufacturing and licensing of performance coatings, including surface modification coating technologies and drug-delivery coating technologies. This segment also manufactures vascular intervention medical devices, including drug-coated balloons, mechanical thrombectomy devices, and radial access balloon catheters and guide sheaths. Geographically, the company derives key revenue from its domestic market.
See More
Previous Close:
$32.44
Open:
$32.32
24h Volume:
101.42K
Relative Volume:
1.32
Market Cap:
$458.29M
Revenue:
$138.20M
Net Income/Loss:
$5.52M
P/E Ratio:
84.34
EPS:
0.38
Net Cash Flow:
$9.86M
1W Performance:
+4.69%
1M Performance:
+10.48%
6M Performance:
-15.99%
1Y Performance:
-23.34%
Surmodics Inc Stock (SRDX) Company Profile
Name
Surmodics Inc
Sector
Industry
Phone
(952) 500-7000
Address
9924 W 74TH ST, EDEN PRAIRIE, MN
Compare SRDX with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
SRDX
Surmodics Inc
|
32.05 | 456.22M | 138.20M | 5.52M | 9.86M | 0.38 |
![]()
ABT
Abbott Laboratories
|
125.64 | 218.92B | 43.11B | 13.98B | 6.66B | 7.98 |
![]()
BSX
Boston Scientific Corp
|
106.21 | 152.62B | 17.55B | 2.03B | 2.72B | 1.37 |
![]()
SYK
Stryker Corp
|
396.66 | 153.22B | 23.22B | 2.86B | 3.58B | 7.40 |
![]()
MDT
Medtronic Plc
|
92.32 | 117.89B | 33.54B | 4.66B | 5.19B | 3.62 |
![]()
EW
Edwards Lifesciences Corp
|
75.80 | 45.12B | 5.54B | 4.18B | 623.10M | 7.00 |
Surmodics Inc Stock (SRDX) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Mar-07-25 | Upgrade | Lake Street | Hold → Buy |
Jun-13-23 | Upgrade | Needham | Hold → Buy |
Feb-13-23 | Downgrade | Needham | Buy → Hold |
Jul-23-20 | Upgrade | Needham | Hold → Buy |
Dec-11-19 | Downgrade | Needham | Buy → Hold |
Nov-01-19 | Downgrade | Lake Street | Buy → Hold |
Aug-01-19 | Reiterated | Needham | Buy |
May-02-19 | Reiterated | Lake Street | Buy |
May-02-19 | Reiterated | Needham | Buy |
Feb-21-19 | Reiterated | Needham | Buy |
May-16-18 | Reiterated | Needham | Buy |
Mar-01-18 | Upgrade | Sidoti | Neutral → Buy |
Feb-28-18 | Reiterated | Lake Street | Buy |
Feb-28-18 | Initiated | Needham | Buy |
Jul-14-17 | Initiated | Lake Street | Buy |
Nov-21-16 | Downgrade | Barrington Research | Outperform → Mkt Perform |
Oct-06-16 | Downgrade | Sidoti | Buy → Neutral |
May-03-16 | Reiterated | Barrington Research | Outperform |
Aug-06-15 | Reiterated | Barrington Research | Outperform |
Mar-27-15 | Initiated | Dougherty & Company | Buy |
Feb-25-14 | Initiated | Laidlaw | Buy |
Aug-01-13 | Upgrade | Feltl & Co. | Buy → Strong Buy |
Nov-12-12 | Reiterated | Barrington Research | Outperform |
View All
Surmodics Inc Stock (SRDX) Latest News
(SRDX) Trading Report - news.stocktradersdaily.com
What analysts say about Surmodics Inc. stockDynamic investment growth - Autocar Professional
Is Surmodics Inc. a good long term investmentLightning-fast growth - Autocar Professional
Surmodics Inc. Stock Analysis and ForecastExceptional growth trajectory - jammulinksnews.com
What makes Surmodics Inc. stock price move sharplyBig Profit Small Risk Alerts - Newser
Minne InnoSurmodics adds to med-device portfolio with $39.9M acquisition of Vetex Medical - The Business Journals
What drives Surmodics Inc. stock priceConsistent wealth multiplication - Autocar Professional
How Surmodics Inc. stock performs during market volatilityFree Expert Investment Advice - Newser
Why Surmodics Inc. stock attracts strong analyst attentionBreakout Setup Scanner - Newser
Surmodics, Inc. (SRDX): A High-Risk, Low-Reward Play in a Weak Momentum and Overvalued Market - AInvest
Zacks Research Reduces Earnings Estimates for Surmodics - Defense World
Cybersecurity Incident at Surmodics Highlights Industry Vulnerabilities - Zenopa
Cyber ThreatsSurmodics confirms cyberattack, says critical systems restored as investigation continues - teiss
SurModics Faces Cyber Incident with IT Systems - TipRanks
Surmodics reports June cyber incident, restores critical IT systems - Investing.com
Surmodics, Inc.(NasdaqGS: SRDX) dropped from Russell 2000 Defensive Index - MarketScreener
Surmodics, Inc. (NASDAQ:SRDX) Shares Bought by Bank of America Corp DE - Defense World
Why Is SurModics (SRDX) Up 6% Since Last Earnings Report? - sharewise
Surmodics, Inc. (NASDAQ:SRDX) Shares Bought by Deutsche Bank AG - Defense World
Surmodics, Inc. (SRDX) Stock Analysis: Exploring a 47.46% Potential Upside in the Medical Devices Sector - DirectorsTalk Interviews
US FTC files amended complaint to block GTCR acquisition of Surmodics - MLex
Surmodics Shares Positive TRANSCEND Trial Results - Medical Product Outsourcing
Illinois and Minnesota AGs Join FTC’s Lawsuit Against Private Equity Firm - regulatoryoversight.com
Surmodics Reports First Quarter of Fiscal Year 2025 Financial Results - ADVFN
Equities Analysts Issue Forecasts for Surmodics Q2 Earnings - Defense World
Legal & General Group Plc Buys 880 Shares of Surmodics, Inc. (NASDAQ:SRDX) - Defense World
Zacks Research Weighs in on Surmodics FY2025 Earnings - Defense World
Are Options Traders Betting on a Big Move in Surmodics Stock? - Yahoo Finance
SRDX Stock Down Following Q2 Earnings Miss, Gross Margin Contracts - TradingView
SurModics: Fiscal Q2 Earnings Snapshot - New Haven Register
Surmodics Inc Stock (SRDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Surmodics Inc Stock (SRDX) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
DANTZKER DAVID | Director |
Feb 13 '25 |
Option Exercise |
27.30 |
5,275 |
144,008 |
44,399 |
BEDOYA JOSE H | Director |
Feb 14 '25 |
Option Exercise |
27.30 |
5,275 |
144,008 |
34,232 |
KNIGHT SUSAN E | Director |
Jan 24 '25 |
Option Exercise |
27.30 |
7,358 |
200,873 |
42,506 |
Arens Timothy J. | Chief Financial Officer |
Nov 26 '24 |
Sale |
39.44 |
7,009 |
276,453 |
70,350 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):